Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:AMX-0035
|
| gptkbp:awards |
Best Places to Work
|
| gptkbp:ceo |
gptkb:Josh_Cohen
gptkb:Michael_Mc_Garrity |
| gptkbp:clinical_trial |
neuroprotective therapies
Phase 2 trial for ALS |
| gptkbp:collaborations |
gptkb:Cleveland_Clinic
|
| gptkbp:focus |
gptkb:psychologist
|
| gptkbp:founded |
gptkb:2013
|
| gptkbp:founder |
gptkb:Josh_Cohen
Justin Klee |
| gptkbp:headquarters |
gptkb:Cambridge,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
Amylyx Pharmaceuticals
|
| gptkbp:ipo |
gptkb:2021
|
| gptkbp:mission |
improve the lives of patients with neurodegenerative diseases.
|
| gptkbp:partnership |
gptkb:University_of_Massachusetts
gptkb:Massachusetts_General_Hospital |
| gptkbp:products |
AM X0035
|
| gptkbp:research_focus |
metabolic pathways
|
| gptkbp:stock_exchange |
gptkb:NASDAQ
|
| gptkbp:website |
www.amylyx.com
|